—Statement from Fred Riccardi, Medicare Rights Center President— Washington DC—The Medicare Rights Center strongly supports the Inflation Reduction Act of
As recently outlined, the Inflation Reduction Act of 2022 incorporates many of Medicare Rights’ long-standing recommendations to meaningfully improve the
Last week, Senate Democrats released updated prescription drug pricing legislation, with the goal of passing it through the reconciliation process
This is part 3 of the helpline trends report series. Read part 1, part 2, and part 4. This third
Medicare Rights recently joined over 70 organizations to launch the campaign “Push For Lower Rx Prices.” The groups are calling
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
A new analysis from the AARP Public Policy Institute finds drug companies have increased prices for many brand name Part
This week, Medicare Rights submitted comments on a proposed rule that would make some important changes to Medicare Advantage (MA)
—Statement from Fred Riccardi, Medicare Rights Center President— Washington DC—The Medicare Rights Center strongly supports the Inflation Reduction Act of
As recently outlined, the Inflation Reduction Act of 2022 incorporates many of Medicare Rights’ long-standing recommendations to meaningfully improve the
Last week, Senate Democrats released updated prescription drug pricing legislation, with the goal of passing it through the reconciliation process
This is part 3 of the helpline trends report series. Read part 1, part 2, and part 4. This third
Medicare Rights recently joined over 70 organizations to launch the campaign “Push For Lower Rx Prices.” The groups are calling
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
A new analysis from the AARP Public Policy Institute finds drug companies have increased prices for many brand name Part
This week, Medicare Rights submitted comments on a proposed rule that would make some important changes to Medicare Advantage (MA)
